

The Gut-Skin Axis: Unraveling the Interplay between Gut Microbiota and Dermatological Health

Haily Fritts^{1*}, Kelly Frasier², Grace Herrick³, Vivian Li⁴, Elizabeth Sebastiao¹, Aria Johnson¹ and Jordan Saunooke¹

¹Idaho College of Osteopathic Medicine, Meridian, ID, USA

²Department of Dermatology, Northwell Health, New Hyde Park, NY, USA

³Alabama College of Osteopathic Medicine, Dothan, AL, USA

⁴Nuvance Health/Vassar Brothers Medical Center, Poughkeepsie, NY, USA

*Corresponding author

Haily Fritts, Idaho College of Osteopathic Medicine, Meridian, ID, USA.

Received: 03 Oct 2024; Published: 20 Oct 2024

Abstract

The bidirectional communication between the gut microbiota and the skin, known as the gut-skin axis, has garnered increasing attention as a novel paradigm in dermatology. This review provides a comprehensive overview of recent research elucidating the role of gut dysbiosis in the pathogenesis of dermatological conditions, including acne, eczema, and psoriasis. Current evidence suggests that alterations in gut microbial composition and dysregulated immune responses contribute to systemic inflammation and skin barrier dysfunction. Moreover, microbial metabolites and immune mediators produced in the gut can influence skin homeostasis and inflammatory processes. Future research directions include investigating microbial-based interventions, such as probiotics, prebiotics, and fecal microbiota transplantation, for modulating the gut microbiota and improving dermatological outcomes. Furthermore, integrated multi-omics approaches and advanced computational modeling hold promise for unraveling complex interactions within the gut-skin axis and identifying potential therapeutic targets for personalized dermatological care.

Introduction

The gut-skin axis (GSA) represents the bidirectional relationship between the gastrointestinal (GI) system and the skin, emphasizing the complex communication pathways and how the health and function of one can significantly influence the other. In dermatology, this concept highlights the role of gut microbiota, intestinal permeability, and systemic inflammation in maintaining skin health and contributing to dermatological diseases. Gut microbiota refers to the diverse community of microorganisms residing in the gastrointestinal tract. Dysbiosis, an imbalance in this microbiome, has been linked to various skin conditions, including acne, rosacea, eczema, and psoriasis [1].

Systemic inflammation is a critical factor in this relationship, where increased intestinal permeability, often termed “leaky gut syndrome,” allows toxins, antigens, and bacteria to translocate into the bloodstream. This can trigger systemic inflammation and subsequent cutaneous manifestations. The rising interest in

the gut-skin axis within the dermatological community reflects its potential to revolutionize the understanding and treatment of skin conditions. For instance, studies indicate that a significant percentage of patients with gastrointestinal disorders such as ulcerative colitis and Crohn’s disease exhibit skin manifestations [2]. Specifically, 14% of patients with ulcerative colitis and 24% of patients with Crohn’s disease show cutaneous lesions, highlighting the interplay between gut and skin health.

This literature review aims to provide a comprehensive overview of current research discussing the role of gut dysbiosis in the pathogenesis of dermatological conditions. This review will scrutinize the mechanisms of action and adverse effects associated with the gut-skin axis by examining clinical trials, randomized controlled studies, and meta-analyses. Additionally, it will explore emerging trends in microbial-based interventions, such as probiotics, prebiotics, and fecal microbiota transplantation, for modulating the gut microbiota and improving dermatological outcomes. Understanding the GSA is crucial for advancing dermatological research and treatment, offering a holistic approach that considers diet, gut health, and systemic inflammation as integral components of managing skin conditions. By synthesizing current evidence and identifying areas for improvement, this review aims to equip dermatologists with a comprehensive understanding of gut-skin interactions, facilitating informed decision-making and enhancing patient-centered care strategies. This analysis is a useful tool for dermatologists, empowering clinicians to make informed decisions and improve the quality of care and outcomes for patients with dermatological conditions influenced by the gut-skin axis.

Role of Gut Dysbiosis in Acne, Eczema, and Psoriasis

Exploration of Gut Dysbiosis in Acne

Recent research has highlighted the significant role of gut microbiota in the development of acne vulgaris. Patients with acne often exhibit distinct alterations in their gut microbial

composition compared to healthy controls, including a notable decrease in beneficial bacteria such as Clostridia, Lachnospiraceae, and Ruminococcaceae and an increase in potentially harmful bacteria like Bacteroides and Proteobacteria [3,4]. These microbial imbalances are believed to exacerbate skin inflammation and contribute to the pathogenesis of acne. Specifically, alterations in gut microbiota composition, such as decreased levels of beneficial bacteria like Bifidobacterium and Lactobacillus and increased levels of Proteobacteria, have been observed in acne patients compared to healthy controls [5]. This imbalance can influence systemic inflammation and immune responses, potentially aggravating acne. Gut dysbiosis can disrupt the skin's microbial balance, promoting the growth of Cutibacterium acnes strains that produce biofilms and lead to antibiotic tolerance, thereby exacerbating acne lesions.

Additional factors to consider for the implications of the GSA include gender-specific variations and the involvement of the brain. Gender-specific differences in gut microbiota have been observed, with male acne patients showing a lower abundance of beneficial microbes and disordered fatty acid metabolism, while female patients exhibit dysbiosis related to amino acid metabolism [6]. These differences suggest hormonal variations between genders may significantly influence gut microbiota composition and metabolic processes. Consequently, therapeutic approaches for acne management may need to be tailored to address these gender-specific microbiota and metabolic differences. The gut-brain-skin axis is another critical pathway through which gut dysbiosis may impact acne. Stress and emotional states, such as anxiety and depression, can alter gut microbiota and increase intestinal permeability, resulting in systemic inflammation that manifests in the skin [7]. Furthermore, therapeutic interventions targeting gut microbiota, such as probiotics, have shown promise in modulating gut and skin microbiota, thereby reducing acne severity [6]. Overall, the intricate relationship between gut dysbiosis and acne underscores the importance of maintaining a balanced gut microbiota for skin health, highlighting potential avenues for novel acne treatments that focus on restoring microbial homeostasis.

Exploration of Gut Dysbiosis in Eczema

Gut dysbiosis significantly contributes to the development and exacerbation of eczema through various mechanisms. It disrupts microbial balance, reduces beneficial metabolites, and impairs immune regulation, highlighting the importance of maintaining a healthy gut microbiome for preventing and managing eczema. Infants with eczema exhibit less complex and stable gut microbial networks than healthy infants, indicating that a denser and more diverse gut microbiota is crucial for healthy development [8]. This dysbiosis is characterized by a lower abundance of beneficial bacteria such as Bifidobacterium and Lactobacillaceae and a higher presence of potentially harmful bacteria like Streptococcus, Bacteroidaceae, and Deinococcaceae, which disrupt the GSA and immune homeostasis [9,10]. The imbalance in gut microbiota leads to reduced production of short-chain fatty acids (SCFAs) like butyrate, essential for maintaining gut barrier integrity and modulating immune responses. This deficiency in SCFAs results in increased IgE levels and altered immune responses, further aggravating eczema symptoms.

In adults with eczema, gut dysbiosis manifests as an altered gut microbiome structure with a dominance of bacteria such as Blautia and Lachnospiraceae, associated with metabolic dysfunctions and immune dysregulation [9]. The gut-skin axis plays a pivotal role in this process, where gut microbiome alterations can lead to changes in the skin microbiome, promoting the colonization of pathogenic bacteria like Staphylococcus aureus (*S. aureus*),

which is known to exacerbate eczema [11]. Additionally, the gut microbiome's interaction with host immunity is crucial, as diminished diversity and specific bacterial deficits are linked to impaired immune development and increased eczema severity. This suggests that targeting the gut microbiome could be viable for managing eczema symptoms and improving overall immune function in affected individuals.

The association between gut dysbiosis and eczema prevalence is well-documented, with multiple studies highlighting the critical role of gut microbiota in the development and progression of eczema. Dysbiosis has been linked to reduced microbial diversity and the prevalence of specific bacterial families that may contribute to eczema. Studies have shown that infants with eczema have a less complex and stable gut microbiota network compared to healthy infants, indicating that a denser and more diverse microbial community may be protective against eczema [12]. Additionally, maternal factors such as high triglyceride levels in late pregnancy have been identified as potential risk factors for eczema, further emphasizing the interconnectedness of maternal health, gut microbiota, and infant health outcomes [8]. Gut dysbiosis plays a significant role in the pathogenesis of eczema and is closely linked to skin barrier disruption. Eczema is a multifactorial disease involving genetic, environmental, and immunological factors, with a notable defect in the epithelial barrier and immune dysregulation. Dysbiosis, characterized by reduced microbial diversity and increased colonization by pathogens like *S. aureus*, exacerbates eczema by impairing the skin barrier and promoting inflammation [13]. The GSA is crucial in this context, as gut microbiota influence systemic immune responses and skin health. Altered gut microbiota can modulate histamine-independent pruritus and disrupt the epidermal barrier through microbial metabolites and proinflammatory cytokines, contributing to central sensitization of pruritus mechanisms in eczema.

The interplay between gut and skin microbiota affects the maturation of innate and adaptive immunity, with early-life microbial exposure being critical for immune development [7,14]. Genetic factors, such as mutations in the filaggrin (FLG) gene, further compromise the skin barrier, making it more susceptible to allergen sensitization and pathogen colonization, which can lead to atopic march, progressing from eczema to food allergies and asthma [15]. The disrupted skin barrier in eczema patients allows for easier bacterial adhesion and reduced antimicrobial peptide production, which favors *S. aureus* colonization and further barrier breakdown [16]. Probiotics and prebiotics have shown promise in modulating the gut microbiome, enhancing the intestinal barrier, and potentially alleviating eczema symptoms by performing immunomodulatory and metabolic effects [17]. Understanding the gut-skin microbiome interaction and its impact on the immune system is essential for developing novel therapeutic strategies for AD [18]. Emerging research continues to shed light on the dynamic relationship between the gut and skin, emphasizing the role of microbial diversity in maintaining immune homeostasis. These findings suggest that targeted interventions to restore microbial balance may offer new avenues for therapeutic approaches.

Analysis of Gut Dysbiosis in Psoriasis

Gut dysbiosis has been increasingly linked to the onset and severity of psoriasis. Patients with psoriasis exhibit significant alterations in their gut microbiota composition compared to healthy individuals. These alterations include a higher abundance of Bacteroidetes and lower levels of Proteobacteria, with specific genera such as Lactobacillus and Dialister more prevalent in psoriatic patients [19]. This dysbiosis is associated

with increased intestinal permeability, often called “leaky gut syndrome,” which allows microbial translocation and systemic immune activation, contributing to chronic inflammation and the phenotypic expression of psoriasis in genetically susceptible individuals [20]. This chronic immune activation plays a role in exacerbating inflammation and triggering the phenotypic expression of psoriasis in genetically predisposed individuals. The GSA, which connects gut microbiota dysbiosis to systemic inflammation, further illustrates how these microbial imbalances influence skin conditions like psoriasis.

The GSA involves complex interactions between the gut microbiome, immune system, and skin health, and it plays a central role in psoriasis pathogenesis. Dysbiosis in psoriasis patients often includes increased levels of Firmicutes and decreased levels of Bacteroidetes, highlighting the critical role of microbial changes in disrupting immune functions and promoting inflammatory pathways [21]. This microbial imbalance affects immune-mediated pathways, particularly the IL-17/IL-23 axis, which is crucial in psoriasis. The IL-17/IL-23 axis is a key driver of the inflammatory response that leads to the proliferation and activation of keratinocytes, resulting in the characteristic skin lesions seen in psoriasis [22]. Modulating the gut microbiota to restore balance could help regulate this inflammatory pathway, offering therapeutic benefits for psoriasis management.

Microbial metabolites, including SCFAs, tryptophan metabolites, and amine derivatives like trimethylamine N-oxide (TMAO), play significant roles in modulating immune responses and inflammation [23]. SCFAs, produced by gut bacteria through the fermentation of dietary fibers, influence the differentiation and function of regulatory T-cells (Tregs), which are essential for maintaining immune homeostasis. In psoriasis, enhancing SCFA production could help regulate immune responses and reduce skin inflammation. Tryptophan metabolites, such as indole derivatives, also possess anti-inflammatory properties that may alleviate psoriasis symptoms [23]. Conversely, TMAO, a metabolite derived from dietary choline and produced by gut bacteria, has been linked to promoting inflammation, potentially worsening psoriatic conditions. The gut microbiota also produces neurotransmitters such as dopamine and serotonin, which interact with the immune system and affect skin inflammation through the gut-brain-skin axis [24]. This bidirectional communication between the gut and skin suggests that maintaining a healthy gut microbiome could positively impact mental and skin health in psoriasis patients.

These findings underscore the critical connection between gut dysbiosis and psoriasis, suggesting that targeting the gut microbiome could be a promising therapeutic approach. Persistent gut dysbiosis, particularly the prevalence of Clostridial species in patients with psoriatic arthritis (PsA), correlates with specific immunological changes not addressed by conventional treatments, indicating an underlying intestinal inflammatory response contributing to PsA pathogenesis [25]. Additionally, treatments like balneotherapy, which improves both skin and gut microbiome composition, suggest that microbiome-targeted therapies can have systemic benefits [26]. Experimental models support these findings, where fecal microbial transplantation from severe psoriasis cases worsened skin inflammation in mild cases, demonstrating gut microbiota’s influence on disease severity [22,27]. Interventions such as probiotics, prebiotics, and fecal microbial transplantation have shown potential in modulating the gut microbiome, restoring microbial balance, and reducing inflammation, ultimately improving clinical outcomes for psoriasis and related conditions [26].

Mechanisms Underlying Gut-Skin Axis Interactions

Impact of Gut Microbial Composition on Systemic Inflammation

Gut dysbiosis plays a significant role in systemic inflammation through various complex mechanisms. Specific microbial species and their metabolites are key contributors to triggering inflammatory responses. For instance, *Streptococcus pneumoniae* (*S. pneumoniae*) produces 2-pentyl furan, which activates microglia through odorant receptors, contributing to neuroinflammation and illustrating the direct connection between gut microbiota and the central nervous system [28]. This emphasizes the broader influence of the gut microbiome beyond the gut itself. Within the intestinal environment, in the gut, microbial sulfonolipids (SoLs), produced by certain bacteria, inhibit toll-like receptor 4 (TLR4) signaling, thereby reducing inflammation [29]. These microbial metabolites have been found to negatively correlate with inflammatory bowel disease (IBD), suggesting that they could act as natural anti-inflammatory agents and potential therapeutic targets for managing conditions like IBD. Furthermore, indolic acids, derived from tryptophan metabolism by gut bacteria, can suppress mitochondrial enzyme activities crucial in bacterial inflammation and sepsis, demonstrating their potential to mitigate systemic inflammation at the mitochondrial level [29].

Tryptophan metabolites exhibit a dual role in inflammation, as indoxyl sulfate promotes vascular inflammation, while indole-3-propionic acid and indole-3-aldehyde offer protective effects against such inflammation. This delicate balance within the gut microbiome highlights the complex interplay between these metabolites and systemic inflammation [29]. Dysbiosis in gut microbiota disrupts the production of metabolites from tryptophan, histidine, and phenylalanine pathways, linking it to inflammatory conditions such as rheumatoid arthritis and colitis. These pathways underscore the potential of metabolic products as biomarkers or therapeutic targets for inflammatory diseases.

Immune dysregulation in the gut profoundly impacts skin barrier integrity, creating a dynamic relationship between microbiota, immune responses, and barrier functions. Conditions like Omenn Syndrome and AD exemplify how dysregulated gut immune responses can extend to peripheral tissues, including the skin [30]. The gut microbiota is essential for maintaining intestinal barrier integrity by producing anti-inflammatory metabolites that protect against mucosal inflammation and systemic endotoxemia [31]. However, dysbiosis increases intestinal permeability, allowing bacterial translocation and endotoxins to enter the bloodstream. This triggers systemic inflammation, contributing to diseases like psoriasis and rheumatoid arthritis [32]. The integrity of the gut barrier is maintained by tight junctions (TJs), and their disruption is linked to various inflammatory diseases [33].

In dermatological conditions like AD, the disruption of epithelial-immune crosstalk leads to allergic inflammation, further illustrating the complex connection between gut and skin [14]. Gut immune responses can also exacerbate skin conditions, as in colitis models, where gut inflammation alters immune responses [25]. The gut microbiome’s role is further underscored by findings that oral therapies, such as intestinal alkaline phosphatase (IAP), can preserve gut barrier function and prevent systemic inflammation following severe injuries, indicating potential therapeutic avenues for dermatological conditions [34]. Additionally, interventions targeting the gut microbiome, such as probiotics and prebiotics, have shown promise in alleviating eczema symptoms by modulating gut microbiota and enhancing barrier integrity. The cross-talk between the gut

and skin microbiomes underscores the importance of a holistic approach to managing dermatological conditions, focusing on local and systemic factors in treatment strategies.

Role of Microbial Metabolites and Immune Mediators in Skin Homeostasis and Inflammation

Microbial species and their metabolites play a pivotal role in skin health by modulating inflammatory pathways and maintaining skin homeostasis. As mentioned, *S. pneumoniae* produces 2-pentylfuran, which contributes to neuroinflammation, while gut-derived SoLs inhibit TLR4 signaling, reducing inflammation associated with IBD [27,35]. Indolic acids from tryptophan metabolism suppress mitochondrial enzymes involved in inflammation, highlighting the potential of microbial metabolites to regulate systemic inflammatory responses [36]. SCFAs, particularly n-butyrate, exhibit anti-inflammatory properties by inhibiting inflammatory responses in intestinal macrophages [37]. These metabolites play a significant role in maintaining intestinal and skin health, influencing conditions like psoriasis and eczema.

Other immune components, such as β -glucan, activate inflammasomes in response to microbial components, leading to the production of proinflammatory cytokines like interleukin (IL)-1 β and IL-18 [38]. The role of microbial metabolites in chronic inflammatory pain, further highlights the connection between gut health and systemic inflammation, as SCFAs and amino acids can influence neural signaling pathways and inflammatory responses. In addition, molecules like 12(S)-HETE, an arachidonic acid metabolite, attenuate TNF- α -induced inflammation by inhibiting the ERK/NF- κ B and C/EBP β signaling pathways in keratinocytes, offering the potential for treating inflammatory skin conditions [39]. The aryl hydrocarbon receptor (AHR) also plays an important role in skin barrier function and immune regulation, with agents like tapinarof being explored for their potential to modulate immune responses and enhance skin defenses.

Autophagy, a cellular process that maintains homeostasis, is impaired in chronic inflammation, particularly in keratinocytes, leading to disrupted epidermal health. Enhancing phospholipid metabolism has shown promise in restoring autophagy and reducing inflammation. Moreover, the gut-brain-skin axis, where gut bacteria produce neurotransmitters like dopamine and serotonin, illustrates how gut health can influence the skin's immune response. The bidirectional communication between the gut and skin suggests that microbiome-targeted therapies could have far-reaching effects on managing inflammatory skin diseases.

Collectins, such as mannose-binding lectin (MBL), are key in pathogen recognition and cytokine modulation, helping maintain skin immune homeostasis by facilitating pathogen clearance and regulating inflammatory responses [9]. Fatty acids, including linoleic acid and polyunsaturated fatty acids (PUFAs), are crucial for regulating immune responses and supporting skin barrier function. Linoleic acid strengthens the skin barrier, while PUFAs balance inflammation, vital in preventing inflammatory skin conditions [40]. Lipid mediators like oxidized phospholipids also play a dual role in inflammatory processes, either exacerbating or mitigating conditions like psoriasis and eczema through their impact on oxidative stress [41]. Chemokines, which direct leukocyte migration, are essential for maintaining immune homeostasis and responding to skin inflammation. Disruption in chemokine signaling can lead to chronic inflammation and impaired immune function, emphasizing the need for balanced

immune responses in maintaining skin health. Furthermore, the interaction between the skin microbiome and inflammatory gene expression through epigenetic mechanisms reveals the complex nature of skin inflammation, suggesting that targeting the microbiome may offer novel approaches for treating skin diseases.

The PI3K/Akt/mTOR pathway is heavily implicated in inflammatory skin diseases such as psoriasis and acne. Inhibiting this pathway using natural or synthetic agents has shown potential for managing inflammation and regulating immune responses in the skin [42]. As research into these pathways progresses, a deeper understanding of their interactions will lead to more targeted treatments that address the underlying mechanisms of skin inflammation and immune dysregulation. These insights are crucial for developing effective therapies that improve patient outcomes in chronic inflammatory skin disorders.

Clinical Implications and Future Research Directions of the Gut-Skin Axis

Prebiotics and Probiotics as Therapeutic Agents

Probiotics and prebiotics have emerged as promising therapeutic options for managing various dermatological conditions by supporting gut microbiota and systemic health. Their mechanisms of action include modulation of gut microbial composition, enhancement of gut barrier function, and regulation of systemic immune responses. Probiotics introduce beneficial bacteria that outcompete pathogenic microbes, while prebiotics, which are non-digestible fibers, stimulate the growth and activity of these beneficial gut bacteria [27]. These interventions strengthen the gut barrier, preventing endotoxins and proinflammatory substances from entering the bloodstream. Additionally, they enhance Tregs and promote the production of anti-inflammatory cytokines. Several randomized controlled trials have demonstrated the beneficial effects of probiotics and prebiotics in conditions like acne, eczema, and psoriasis. For example, a 17-week study by Wastyk et al. showed reduced inflammatory markers and increased microbiota diversity with a diet rich in fermented foods [43]. However, further research is necessary to investigate specific strains, formulations, and these interventions' long-term safety and efficacy.

Clinicians must be mindful of the current lack of quality control in producing probiotics, particularly those marketed as supplements [44]. The absence of standardized formulations can hinder effective treatment, making it essential for healthcare professionals to research and prescribe probiotics for specific medical conditions. Improvements in regulation and accountability are critical for the reliable use of prebiotics and probiotics. An interdisciplinary approach that involves gastroenterologists, microbiologists, and nutritionists is essential when prescribing these agents to optimize outcomes. Despite challenges, probiotics and prebiotics hold great potential for dermatological treatment, and clinicians should consider incorporating them cautiously into treatment plans.

The Future of Fecal Microbiota Transplantation (FMT)

Fecal microbiota transplantation (FMT) represents an alternative approach to introducing healthy gut bacteria by transplanting fecal matter from a healthy donor into the recipient's gastrointestinal tract. This intervention can potentially re-establish a balanced microbial ecosystem, outcompete pathogenic bacteria, and improve gut barrier function, reducing intestinal permeability and systemic inflammation. Unlike probiotics and prebiotics, FMT alters the gut microbiota on a larger scale, leading to more sustained treatment outcomes. While FMT is primarily used for

severe gastrointestinal infections, preliminary studies suggest it may also benefit dermatological conditions.

Polak et al. reported that a 36-year-old male with psoriasis experienced significant improvement in body surface area affected by the condition and quality of life following two FMT procedures.²⁰ His IBD was also completely relieved, indicating the multidimensional benefits of FMT. This highlights FMT's potential to address dermatological and gastrointestinal conditions by targeting the gut microbiome. Although these findings are promising, further clinical trials are necessary to determine the long-term efficacy and safety of FMT for skin diseases. Additionally, exploring topical treatments that modulate the skin microbiome offers a complementary approach to restoring skin health.

Diet and Nutrition

Integrating dietary assessment into patient care is critical for addressing underlying issues related to gut microbiota and its impact on skin health. Diets high in chocolate, cholesterol, fat, dairy, and foods with a high glycemic index are strongly associated with acne exacerbation. These dietary components promote inflammation, disrupt the gut microbiome, and increase sebum production, leading to clogged pores and worsened acne [45]. Conversely, diets rich in vegetables, fruits, and fatty acids protect against acne due to their anti-inflammatory properties and positive influence on gut microbiota diversity. Specifically, a high glycemic load can alter the mTOR pathway, a key signaling pathway involved in cell growth and metabolism, which can increase the risk of acne by promoting hyperkeratinization and inflammation [46].

Collaboration between dermatologists and dietitians is essential to address skin conditions through dietary interventions effectively. Dermatologists can diagnose and monitor skin conditions, while dietitians provide tailored nutritional advice that supports gut health. This interdisciplinary approach ensures comprehensive care, potentially reducing reliance on pharmaceutical treatments. Educating patients about the relationship between diet and skin health empowers them to make healthier choices that benefit their gut and skin. Future research should focus on identifying specific dietary components that most significantly affect the gut-skin axis and integrating these findings into dermatological practice to improve patient outcomes.

Exploration of Integrated Multi-Omics Approaches

The use of integrated multi-omics approaches, which combine genomics, transcriptomics, proteomics, metabolomics, and microbiomics, is gaining momentum in understanding the gut-skin axis. These comprehensive analyses offer a holistic view of the biological systems involved, allowing researchers to uncover the complex interactions between the gut and the skin [47]. A recent multi-omics technique study revealed significant metabolite profile changes associated with city pollution exposure, demonstrating how external factors influence skin metabolism and microbiome composition [48]. By integrating metabolomic, microbiomic, and environmental data, researchers can better understand how gut microbiota impacts skin health, leading to novel therapeutic targets for dermatological conditions.

Despite the potential of multi-omics approaches, challenges such as data types' heterogeneity and datasets' high dimensionality must be addressed. Developing robust computational methods and standardizing protocols across studies will be essential for extracting meaningful insights from multi-omics data. Further research should focus on refining these analytical frameworks to

better understand individual variations in disease pathogenesis and treatment responses. By leveraging integrated multi-omics data, researchers can advance personalized medicine approaches that target the specific needs of individual patients, leading to more effective treatments for dermatological conditions.

Utilization of Advanced Computational Modeling

Advanced computational modeling is increasingly vital for predicting therapeutic responses and identifying biomarkers in dermatology, driven by the availability of large-scale omics data and advancements in computational power. For example, models combining microbiome profiles with clinical data have been developed to predict responses to probiotic treatments in patients with vitiligo [49]. By analyzing the unique microbial composition of each patient, these models identify the most effective probiotic strains, allowing for customized treatments that maximize therapeutic benefits while minimizing adverse effects. Recent developments in machine learning and artificial intelligence have enabled the creation of predictive models that forecast therapeutic outcomes based on patient-specific omics data. These models integrate various data types, including genomic, transcriptomic, proteomic, and microbiome profiles and clinical data, to provide a comprehensive picture of a patient's health status. These models leverage machine learning techniques and sophisticated algorithms to analyze vast data, uncovering intricate patterns and relationships that inform clinical decision-making and personalized treatment strategies.

Computational models have also been influential in pinpointing novel biomarkers for skin diseases. These models can sift through genomic and proteomic data to identify specific genes or proteins associated with disease severity or treatment response [50]. These biomarkers can then be used to monitor disease progression and treatment efficacy or to develop diagnostic tests. Within the framework of the gut-skin axis, computational models can analyze microbiome data to classify key microbial markers that correlate with skin health, providing insights into the mechanisms underlying skin diseases and identifying prospective targets for therapeutic mediation. Major improvements through advanced computational modeling in biomarker discovery include enhanced diagnostic accuracy, predicting disease risk, and developing targeted therapies that address the root causes of dermatological conditions. As computational techniques continue to advance, their integration into dermatological research and clinical practice will lead to further breakthroughs. Joint efforts between computational biologists, dermatologists, and clinical researchers are essential for the progression of personalized therapeutic strategies. Establishing interdisciplinary teams and fostering communication between these fields will be crucial for translating computational insights into clinical practice, enhancing our understanding of the gut-skin axis, and unraveling its complexities.

Challenges to Interdisciplinary Approaches

The gut-skin axis is significant in current dermatology literature, with implications for conditions such as acne vulgaris, eczema, and psoriasis [1]. An interdisciplinary team approach is crucial given the prevalence of skin conditions linked to gut microbiome imbalances. This approach could involve genomic analysis of both skin and gut microbiomes, the prescription of prebiotics and probiotics, and dietary modifications tailored to the patient's needs. However, integrating gut health into dermatological treatment plans presents challenges such as increased cost, time demands, and the need for a coordinated team of specialists.

Despite these challenges, the potential of addressing both gut and skin health as interconnected systems could lead to more successful treatment outcomes. Future research should investigate the cost-effectiveness and efficacy of incorporating gut microbiome analysis into dermatological workups. Additionally, randomized controlled trials should be conducted to evaluate the benefits of prebiotics and probiotics in managing skin conditions like eczema and psoriasis. The future of dermatology lies in integrating clinical practice with advanced research on the gut-skin axis, using personalized approaches and microbial-based interventions to improve patient outcomes.

Conclusion

The gut-skin axis, representing the bidirectional communication between gut microbiota and the skin, is an emerging area of interest in dermatology with significant implications for understanding and treating dermatological conditions. Recent research has elucidated the role of gut dysbiosis in the pathogenesis of conditions such as acne, eczema, and psoriasis, highlighting how alterations in gut microbial composition and dysregulated immune responses can lead to systemic inflammation and skin barrier dysfunction. Microbial metabolites and immune mediators produced in the gut have been shown to influence skin homeostasis and inflammatory processes, underscoring the intricate link between gut health and skin health.

Research into the gut-skin axis reveals promising medical treatments, including prebiotics and probiotics, fecal microbiota transplantation, integrated multi-omic approaches, and advanced computational modeling. By exploring the gut-skin connection, personalized and innovative care strategies can be developed. Further research in this area will enable physicians to enhance the standard of treatment for various dermatologic and gastroenterologic conditions, thereby improving patient outcomes, adherence, and satisfaction. Future research should focus on microbial-based interventions to modulate the gut microbiota and improve dermatological outcomes. Additionally, integrated multi-omics approaches and advanced computational modeling offer promising avenues for unraveling the complex interactions within the gut-skin axis and identifying potential therapeutic targets for personalized care. As understanding of this axis deepens, it holds the potential to revolutionize dermatological treatment, paving the way for innovative, individualized therapies that address both gut and skin health.

References

- De Pessemier B, Grine L, Debaere M, Maes A, Paetzold B, et al. (2021) Gut–Skin Axis: Current Knowledge of the Interrelationship between Microbial Dysbiosis and Skin Conditions. *Microorganisms* 9: 353.
- He R, Zhao S, Cui M, Chen Y, Ma J, et al. (2023) Cutaneous manifestations of inflammatory bowel disease: basic characteristics, therapy, and potential pathophysiological associations. *Front Immunol* 14: 1234535.
- Deng Y, Wang H, Zhou J, Mou Y, Wang G, et al. (2018) Patients with Acne Vulgaris Have a Distinct Gut Microbiota in Comparison with Healthy Controls. *Acta Derm Venereol* 98: 783-790.
- Yan H, Zhao H, Guo D, Zhu P, Zhang C, et al. (2018) Gut microbiota alterations in moderate to severe acne vulgaris patients. *J Dermatol* 45: 1166-1171.
- Cavallo I, Sivori F, Truglio M, Maio FD, Lucantoni F, et al. (2022) Skin dysbiosis and *Cutibacterium acnes* biofilm in inflammatory acne lesions of adolescents. *Sci Rep* 12: 21104.
- Huang C, Zhuo F, Han B, Li W, Jiang B, et al. (2023) The updates and implications of cutaneous microbiota in acne. *Cell Biosci* 13: 113.
- Lee YB, Byun EJ, Kim HS (2019) Potential Role of the Microbiome in Acne: A Comprehensive Review. *J Clin Med* 8: 987.
- Huang L, Pan G, Feng Y, Fan Z, Ma K, et al. (2023) Microbial network signatures of early colonizers in infants with eczema. *iMeta* 2: e90.
- Wang Y, Hou J, Tsui JCC, Wang L, Zhou J, et al. (2022) Unique gut microbiome signatures among adult patients with moderate to severe atopic dermatitis in southern Chinese doi:10.1101/2022.05.14.491964.
- Lee MJ, Park YM, Kim B, Tae IH, Kim NE, et al. (2022) Disordered development of gut microbiome interferes with the establishment of the gut ecosystem during early childhood with atopic dermatitis. *Gut Microbes* 14: 2068366.
- Ahn K (2023) The Effect of Prebiotics on Atopic Dermatitis. *Allergy Asthma Immunol Res* 15: 271.
- Zheng H, Liang H, Wang Y, Miao M, Shi T, et al. (2016) Altered Gut Microbiota Composition Associated with Eczema in Infants. *Planet PJ*, ed. *PLOS ONE* 11: e0166026.
- Iwatsuki K, Yamasaki O, Morizane S (2018) Microbiome, Dysbiosis, and Atopic Dermatitis. In: Katayama I, Murota H, Satoh T, eds. *Evolution of Atopic Dermatitis in the 21st Century*. Springer Singapore 2018: 141-155.
- Kim JE, Kim HS (2019) Microbiome of the Skin and Gut in Atopic Dermatitis (AD): Understanding the Pathophysiology and Finding Novel Management Strategies. *J Clin Med* 8: 444.
- Kost Y, Muskat A, Mhaimed N, Nazarian RS, Kobets K (2022) Exosome therapy in hair regeneration: A literature review of the evidence, challenges, and future opportunities. *J Cosmet Dermatol* 21: 3226-3231.
- Braun C, Patra V, Lina G, Nicolas JF, Vocanson M, et al. (2022) The role of skin dysbiosis in atopic dermatitis: *Eur J Dermatol* 32: 439-444.
- Khanna N, Devi P, Kumar A, Pawar SV (2021) Probiotics for Atopic Dermatitis. In: Pawar SV, Rishi P, eds. *Probiotic Research in Therapeutics*. Springer Singapore 2021: 335-362.
- Bauer SM (2017) Atopic Eczema: Genetic Associations and Potential Links to Developmental Exposures. *Int J Toxicol* 36: 187-198.
- Guo X, Huang C, Xu J, Xu H, Liu L, et al. (2022) Gut Microbiota Is a Potential Biomarker in Inflammatory Bowel Disease. *Front Nutr* 8: 818902.
- Polak K, Bergler-Czop B, Szczepanek M, Wojciechowska K, Frątczak A, et al. (2021) Psoriasis and Gut Microbiome—Current State of Art. *Int J Mol Sci* 22: 4529.
- Xiao X, Hu X, Yao J, Cao W, Zou Z, et al. (2023) The role of short-chain fatty acids in inflammatory skin diseases. *Front Microbiol* 13: 1083432.
- Hsu DK, Fung MA, Chen HL (2020) Role of skin and gut microbiota in the pathogenesis of psoriasis, an inflammatory skin disease. *Med Microecol* 4: 100016.
- Stec A, Sikora M, Maciejewska M, Stec KP, Michalska M, et al. (2023) Bacterial Metabolites: A Link between Gut Microbiota and Dermatological Diseases. *Int J Mol Sci* 24: 3494.
- Choy CT, Chan UK, Siu PLK, Zhou J, Wong CH, et al. (2023) A Novel E3 Probiotics Formula Restored Gut Dysbiosis and Remodelled Gut Microbial Network and Microbiome Dysbiosis Index (MDI) in Southern Chinese Adult Psoriasis Patients. *Int J Mol Sci* 24: 6571.
- Castelino M, Ijaz UZ, Tutino M, MacDonald E, Fragoulis

- GE, et al. (2023) The stool microbiome in patients with psoriatic arthritis is altered but, unlike the skin microbiome, does not change following treatment: evidence for an underlying inflammatory drive from the intestine. Published online doi:10.1101/2023.05.18.23289979.
26. Merana GR, Dwyer LR, Dhariwala MO, Weckel A, Gonzalez JR, et al. (2022) Intestinal inflammation alters the antigen-specific immune response to a skin commensal. *Cell Rep* 39: 110891.
 27. Buhaş MC, Gavrilaş LI, Candrea R, Cătinean A, Mocan A, et al. (2022) Gut Microbiota in Psoriasis. *Nutrients* 14: 2970.
 28. Porcari S, Benech N, Valles-Colomer M, Segata N, Gasbarrini A, et al. (2023) Key determinants of success in fecal microbiota transplantation: From microbiome to clinic. *Cell Host Microbe* 31: 712-733.
 29. Paeslack N, Mimmler M, Becker S, Gao Z, Khuu MP, et al. (2022) Microbiota-derived tryptophan metabolites in vascular inflammation and cardiovascular disease. *Amino Acids* 54: 1339-1356.
 30. Zhu TH, Zhu TR, Tran KA, Sivamani RK, Shi VY (2018) Epithelial barrier dysfunctions in atopic dermatitis: a skin-gut-lung model linking microbiome alteration and immune dysregulation. *Br J Dermatol* 179: 570-581.
 31. Wei Y, Gao J, Kou Y, Liu M, Meng L, et al. (2020) The intestinal microbial metabolite desaminotyrosine is an anti-inflammatory molecule that modulates local and systemic immune homeostasis. *FASEB J* 34: 16117-16128.
 32. Jacob S, Jacob DG (2019) Infectious Threats, the Intestinal Barrier, and Its Trojan Horse: Dysbiosis. *Front Microbiol* 10: 1676.
 33. Panwar S, Sharma S, Tripathi P (2021) Role of Barrier Integrity and Dysfunctions in Maintaining the Healthy Gut and Their Health Outcomes. *Front Physiol* 12: 715611.
 34. Adiliaghdam F, Cavallaro P, Mohad V, Almpani , Kuhn F, et al. (2020) Targeting the gut to prevent sepsis from a cutaneous burn. *JCI Insight* 5: e137128.
 35. Park YJ, Lee HK (2018) The Role of Skin and Orogenital Microbiota in Protective Immunity and Chronic Immune-Mediated Inflammatory Disease. *Front Immunol* 8: 1955.
 36. Fedotcheva N, Beloborodova N (2022) Influence of Microbial Metabolites and Itaconic Acid Involved in Bacterial Inflammation on the Activity of Mitochondrial Enzymes and the Protective Role of Alkalinization. *Int J Mol Sci* 23: 9069.
 37. Arpaia N, Rudensky AY (2014) Microbial metabolites control gut inflammatory responses. *Proc Natl Acad Sci* 111: 2058-2059.
 38. Tavares AH, Bürgel PH, Bocca AL (2015) Turning Up the Heat: Inflammasome Activation by Fungal Pathogens. Heitman J, ed. *PLOS Pathog* 11: e1004948.
 39. Jeon KB, Kim J, Lim CM, Park JY, Kim NY, et al. (2023) Unsaturated Oxidated Fatty Acid 12(S)-HETE Attenuates TNF- α Expression in TNF- α /IFN- γ -Stimulated Human Keratinocyte Cells. Published online doi:10.2139/ssrn.4352856.
 40. Kiezel-Tsugunova M, Kendall AC, Nicolaou A (2018) Fatty acids and related lipid mediators in the regulation of cutaneous inflammation. *Biochem Soc Trans* 46: 119-129.
 41. Valacchi G, De Luca C, Wertz PW (2010) Lipid Mediators in Skin Inflammation: Updates and Current Views. *Mediators Inflamm* 2010: 1-2.
 42. Roy T, Boateng ST, Uddin MB, Mbeumi SB, Yadav RK, et al. (2023) The PI3K-Akt-mTOR and Associated Signaling Pathways as Molecular Drivers of Immune-Mediated Inflammatory Skin Diseases: Update on Therapeutic Strategy Using Natural and Synthetic Compounds. *Cells* 12: 1671.
 43. Wastyk HC, Fragiadakis GK, Perelman D, Dahan D, Merrill BD, et al. (2021) Gut-microbiota-targeted diets modulate human immune status. *Cell* 184: 4137-4153.
 44. Da Silva EM, Alves RW, Doretto-Silva L, Andrade-Oliveira V (2023) Cross-Talk Between Gut Microbiota and Immune Cells and Its Impact on Inflammatory Diseases. In: Ribeiro De Araujo D, Carneiro-Ramos M, eds. *Biotechnology Applied to Inflammatory Diseases. Interdisciplinary Biotechnological Advances*. Springer Nature Singapore 139-162.
 45. Dall'Oglio F, Nasca MR, Fiorentini F, Micali G (2021) Diet and acne: review of the evidence from 2009 to 2020. *Int J Dermatol* 60: 672-685.
 46. Sánchez-Pellicer P, Navarro-Moratalla L, Núñez-Delegido E, Ruzafa-Costas B, Agüera-Santos J, et al. (2022) Acne, Microbiome, and Probiotics: The Gut–Skin Axis. *Microorganisms* 10: 1303.
 47. Lloyd-Price J, Arze C, Ananthakrishnan AN, Schirmer M, Pacheco JA, et al. (2019) IBDMDB Investigators, Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. *Nature* 569: 655-662.
 48. Misra N, Clavaud C, Guinot F, Bourokba N, Nouveau S, et al. (2021) Multi-omics analysis to decipher the molecular link between chronic exposure to pollution and human skin dysfunction. *Sci Rep* 11: 18302.
 49. Ni Q, Ye Z, Wang Y, Chen J, Zhang W, et al. (2020) Gut Microbial Dysbiosis and Plasma Metabolic Profile in Individuals with Vitiligo. *Front Microbiol* 11: 592248.
 50. Reel PS, Reel S, Pearson E, Trucco E, Jefferson E (2021) Using machine learning approaches for multi-omics data analysis: A review. *Biotechnol Adv* 49: 107739.

Copyright: ©2024 Haily Fritts et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Citation: Haily Fritts, Kelly Frasier, Grace Herrick, Vivan Li, Elizabeth, et al. The Gut-Skin Axis: Unraveling the Interplay between Gut Microbiota and Dermatological Health. *Int J Immu & Micro* 2024 1: 1-7.